Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation

What Was Tested

This randomized controlled trial looks at Insulin Lispro and NPH Insulin (isophane).

To determine insulin kinetics and overnight glycemic control after bedtime administration of a new intermediate-acting insulin preparation called neutral protamine lispro (NPL).

Who Took Part

According to the abstract, 12 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Insulin Lispro study, the assignments were hidden from both participants and investigators until the end.

In the crossover set-up each of the patients took both Insulin Lispro and the comparison in turn, acting as their own control.

The study had a double-blind, randomized, crossover design.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Circadian Rhythm, Diabetes Mellitus, Type 1, Drug Combinations, Glucose Clamp Technique, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Lispro and NPH Insulin (isophane) in 12 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1997 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page and the NPH Insulin (isophane) compound page, all human trials.